<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-related <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ligand (TRAIL), a member of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) family, binds to several cell-surface receptors with distinct functions (agonistic receptors 1 and 2 [TRAIL-R1, TRAIL-R2]; decoy receptors 3 and 4 [TRAIL-R3, TRAIL-R4]) </plain></SENT>
<SENT sid="1" pm="."><plain>Expression and function was characterized in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) </plain></SENT>
<SENT sid="2" pm="."><plain>While <z:mpath ids='MPATH_458'>normal</z:mpath> marrow showed negligible expression of TRAIL and receptors (except TRAIL-R3), TRAIL and <z:hpo ids='HP_0000001'>all</z:hpo> receptors were constitutively expressed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> marrow </plain></SENT>
<SENT sid="3" pm="."><plain>Following TRAIL exposure, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> marrow showed significant increases in <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, whereas <z:mpath ids='MPATH_458'>normal</z:mpath> marrow, except for a subset of CD34+ precursors, did not (P =.012) </plain></SENT>
<SENT sid="4" pm="."><plain>Marrow from 21 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was then propagated in long-term cultures in the presence or absence of TRAIL </plain></SENT>
<SENT sid="5" pm="."><plain>While in advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>] and tAML [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> transformed into <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>]), colony numbers decreased in the presence of TRAIL (63.0% +/- 10.4% of untreated group [100%]), numbers increased in patients with RA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> (160.2% +/- 90.5% of untreated group) </plain></SENT>
<SENT sid="6" pm="."><plain>TRAIL eliminated preferentially clonally abnormal cells as identified by chromosomal markers </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, TRAIL and receptor expression differed significantly between <z:mpath ids='MPATH_458'>normal</z:mpath> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> marrow, and TRAIL modulated in vitro hemopoiesis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> dependent upon disease stage but not, to a detectable extent, in <z:mpath ids='MPATH_458'>normal</z:mpath> marrow </plain></SENT>
</text></document>